Benzathine benzylpenicillin

Brand Names: Penadur LA, Penidure, Bicillin L-A

Drug Class: Natural penicillin antibiotic, beta-lactam antibacterial

Overview

Benzathine benzylpenicillin is a long-acting penicillin antibiotic used primarily for the treatment and prevention of certain bacterial infections, particularly group A streptococcal infections and syphilis. It provides sustained antibacterial activity through slow absorption from intramuscular injection sites.

Mechanism of Action

Benzathine benzylpenicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death. The benzathine component provides prolonged release from intramuscular injection sites, maintaining therapeutic levels for extended periods.

Indications

  • Treatment of group A streptococcal upper respiratory tract infections
  • Secondary prevention of rheumatic fever
  • Treatment of syphilis (all stages)
  • Prophylaxis against recurrent rheumatic fever
  • Treatment of yaws, bejel, and pinta

Dosage

Administered by deep intramuscular injection only. Adult dosage: For streptococcal infections: 1.2 million units single dose. For syphilis: 2.4 million units single dose (early syphilis) or weekly doses for 3 weeks (late syphilis). Pediatric dosage: Based on weight and indication. Never administer intravenously.

Contraindications

  • Hypersensitivity to penicillins or other beta-lactam antibiotics
  • History of severe allergic reactions to penicillin
  • Intravenous administration
  • Use in patients with history of penicillin-associated hemolytic anemia

Side Effects

  • Injection site reactions (pain, tenderness, induration)
  • Hypersensitivity reactions (rash, urticaria, anaphylaxis)
  • Gastrointestinal disturbances
  • Headache, dizziness
  • Fever
  • Hemolytic anemia
  • Thrombocytopenia
  • Neurotoxicity with high doses

Interactions

  • Probenecid decreases renal tubular secretion of penicillin
  • Tetracyclines may antagonize bactericidal effects
  • Oral contraceptives: reduced efficacy reported
  • Methotrexate: increased toxicity risk
  • Warfarin: potential increased anticoagulant effect